Mechanism of Antiplatelet Action
The primary goal of dipyridamole is to prevent platelet aggregation. Its core mechanism involves increasing intracellular cyclic adenosine monophosphate (cAMP) within platelets. As a result of elevated cAMP, the concentration of calcium ions ($Ca^{2+}$) in the cytoplasm drops sharply. Without calcium, the aggregation process is blocked, partly due to the inactivation of key receptors such as glycoprotein GP IIb/IIIa.
This effect is achieved through three main pathways:
- Phosphodiesterase (PDE) Inhibition: The drug directly blocks the enzyme that normally degrades cAMP, thereby promoting its intracellular accumulation.
- Adenosine Uptake Blockade: Dipyridamole prevents the reuptake of adenosine by erythrocytes and endothelial cells. As a result, adenosine remains in the blood plasma.
- Inhibition of Adenosine Metabolism: The drug inhibits adenosine deaminase, protecting adenosine from breakdown.
Adenosine Pathway and Mediator Effects
The accumulation of adenosine in the blood is a crucial step in pharmacodynamics. Free adenosine actively stimulates $A_2$ receptors located on the platelet membrane. Activation of these receptors triggers adenylate cyclase, ultimately leading to robust cAMP synthesis.
Additionally, dipyridamole interferes with other enzymes and mediators:
- Thromboxane Synthase Inhibition: Suppresses the synthesis of thromboxane $A_2$, one of the most potent inducers of aggregation.
- Prostacyclin Stimulation: The drug prompts endothelial cells to release more prostacyclin—a natural factor preventing blood clotting.
- Vascular Effect: Elevated cAMP levels occur not only in platelets but also in vascular smooth muscle cells, causing relaxation and vasodilation.
Clinical Use and Combinations
Historically developed as a coronary vasodilator, dipyridamole's primary role today is thrombosis prevention. Due to its relatively weak standalone antiplatelet effect, it is rarely used as monotherapy. It is prescribed in combination regimens:
- Peripheral Artery Disease and Ischemic Stroke Prevention: Used in strict combination with acetylsalicylic acid (ASA) for synergistic antithrombotic effects.
- Heart Valve Replacement: Essential for preventing thrombus formation on mechanical heart valves, typically prescribed alongside oral anticoagulants (e.g., warfarin).
Dosing Regimen and pH Dependency
The administration of dipyridamole depends heavily on its formulation, as gastrointestinal absorption is critically dependent on environmental acidity (pH).
- Standard Formulation: Taken 3–4 times daily. It is critical to take tablets on an empty stomach (1 hour before meals) to ensure optimal absorption.
- Extended-Release Formulation: Taken twice daily, preferably with meals.
Drug Interactions: Dipyridamole absorption decreases sharply when gastric pH rises. Therefore, concurrent use with antisecretory drugs (proton pump inhibitors, $H_2$ blockers) is strictly discouraged as they impair the bioavailability of the antiplatelet agent.
Safety Profile and Side Effects
The comparative risk of bleeding with dipyridamole is lower than with acetylsalicylic acid. However, adverse reactions still occur and are driven by both systemic and vascular actions:
- Cardiovascular and CNS: Vasodilation can cause arterial hypotension, dizziness, and headache.
- Gastrointestinal: Dyspepsia, including nausea and discomfort.
- Allergic Reactions: Skin rashes.
Key Contraindication: Stable angina. This risk is linked to the potential development of steal syndrome, which can critically worsen myocardial ischemia.